ZNF228 Inhibitors
Chemical inhibitors of ZNF228 can play a role in modulating the function of this protein through various mechanisms. E-64, as a cysteine protease inhibitor, can prevent the cleavage of ZNF228, which is a process that often regulates protein activity and lifespan. Similarly, ALLN targets calpains, another group of cysteine proteases, and its inhibitory action can lead to the stabilization of ZNF228 by averting proteolytic degradation. Proteasomal inhibitors such as MG-132 and Lactacystin are particularly significant because they block the ubiquitin-proteasome pathway, a cellular mechanism responsible for degrading and recycling proteins. By preventing the degradation of ZNF228, these inhibitors can lead to an accumulation of the protein, which can affect its overall function.
Additionally, several inhibitors target different kinases that are responsible for the phosphorylation of proteins, which is a common regulatory mechanism. PD98059 and U0126, both MEK inhibitors, can interfere with the MAPK/ERK pathway, which may be involved in the regulation of ZNF228, leading to its inhibition. LY294002 and Wortmannin, both PI3K inhibitors, can interfere with the PI3K/Akt pathway and, as a result, can inhibit any regulatory effect this pathway has on ZNF228. The p38 MAPK inhibitor SB203580 and the JNK inhibitor SP600125 can also impede pathways potentially involved in the activity and stability of ZNF228. Finally, Staurosporine, a broad-spectrum kinase inhibitor, can inhibit a wide range of kinases, thereby preventing the phosphorylation of ZNF228 that would otherwise modulate its function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E-64 is a potent inhibitor of cysteine proteases. If ZNF228 is subject to regulation by proteolytic cleavage, which is a common regulatory mechanism for many proteins, inhibition of these proteases by E-64 could prevent the maturation or degradation of ZNF228, thereby inhibiting its function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 inhibits the proteasome, a protein complex responsible for degrading many proteins through ubiquitination. By inhibiting proteasomal activity, MG-132 could prevent the degradation of ZNF228, potentially leading to an accumulation of non-functional ZNF228 that has been ubiquitinated for degradation but not processed. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is another proteasome inhibitor. Similar to MG-132, if ZNF228 is regulated by ubiquitin-proteasome-mediated degradation, lactacystin would inhibit this pathway, leading to inhibition of ZNF228 function due to an accumulation of ubiquitinated, non-functional forms. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is involved in the MAPK/ERK pathway. If ZNF228 is functionally regulated by this pathway, perhaps by phosphorylation that affects its activity, PD98059 would inhibit this modification, leading to ZNF228 inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. If ZNF228 is downstream of PI3K/Akt signaling and relies on this pathway for its activity, possibly through phosphorylation, LY294002 would inhibit this signaling and thereby inhibit ZNF228 function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK. If ZNF228 is activated or stabilized by p38 MAPK signaling, SB203580 would inhibit this pathway, leading to inhibition of ZNF228 function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK. If ZNF228 activity is modulated by JNK signaling, potentially through direct phosphorylation or regulation of associated factors, inhibition of JNK by SP600125 would lead to inhibition of ZNF228 function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2. If the function of ZNF228 depends on the MAPK/ERK pathway, U0126 would inhibit this signaling and therefore inhibit ZNF228 function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor. If the activity of ZNF228 is contingent upon PI3K/Akt pathway signaling, Wortmannin would inhibit this pathway, leading to inhibition of ZNF228 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which could affect the activity of ZNF228 if it is involved in mTOR signaling pathways. Inhibition of mTOR by Rapamycin would thus inhibit ZNF228 function. | ||||||